Pharmacological Management of Obesity Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Pharmacological Management of Obesity. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Pharmacological Management of Obesity Indian Medical PG Question 1: Which of the following enzymes is not targeted by hypolipidemic drugs?
- A. HMG Co A reductase
- B. Lipoprotein lipase
- C. Acyl CoA, cholesterol acyl transferase 1
- D. Peripheral decarboxylase (Correct Answer)
Pharmacological Management of Obesity Explanation: ***Peripheral decarboxylase***
- **Peripheral decarboxylase** (also known as DOPA decarboxylase) is involved in the synthesis of dopamine from L-DOPA and is a target for drugs used in **Parkinson's disease**, not hypolipidemic drugs.
- Its inhibition by drugs like **carbidopa** or **benserazide** prevents the peripheral conversion of L-DOPA to dopamine, increasing L-DOPA availability for the brain.
*HMG Co A reductase*
- **HMG-CoA reductase** is the rate-limiting enzyme in cholesterol biosynthesis and is the primary target for **statins** (e.g., atorvastatin, simvastatin).
- Statins effectively lower **LDL cholesterol** by inhibiting this enzyme, reducing endogenous cholesterol production.
*Lipoprotein lipase*
- **Lipoprotein lipase (LPL)** activity can be enhanced by certain hypolipidemic drugs, such as **fibrates**, which activate **PPAR-α**.
- Increased LPL activity leads to enhanced hydrolysis of **triglycerides** from VLDL and chylomicrons, reducing triglyceride levels in plasma.
*Acyl CoA, cholesterol acyl transferase 1*
- **Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors** were developed as potential hypolipidemic agents to prevent cholesterol esterification and absorption.
- While not widely used clinically due to efficacy and side effect profiles, **ACAT1** is involved in cholesterol esterification in the intestine and liver, making it a target for reducing cholesterol absorption.
Pharmacological Management of Obesity Indian Medical PG Question 2: Which of the following drugs used to treat type II diabetes mellitus causes weight loss?
- A. Metformin (Correct Answer)
- B. Glimepiride
- C. Repaglinide
- D. Gliclazide
Pharmacological Management of Obesity Explanation: ***Metformin***
- **Metformin** often leads to **modest weight loss** as it improves insulin sensitivity and reduces hepatic glucose production.
- It works by activating **AMPK**, which can suppress appetite and reduce fat storage.
*Glimepiride*
- **Glimepiride** is a **sulfonylurea** that stimulates insulin release from pancreatic beta cells.
- This mechanism often leads to **weight gain** due to increased insulin levels.
*Repaglinide*
- **Repaglinide** is a **meglitinide**, which, like sulfonylureas, increases insulin secretion in a glucose-dependent manner.
- This increased insulin secretion can also result in **weight gain**.
*Gliclazide*
- **Gliclazide** is another **sulfonylurea** that works by increasing insulin secretion from the pancreas.
- Similar to other sulfonylureas, its use is commonly associated with **weight gain**.
Pharmacological Management of Obesity Indian Medical PG Question 3: What is the mechanism of action of Tegaserod?
- A. 5HT3 receptor antagonist
- B. Dopamine D2 receptor antagonist
- C. 5HT4 receptor agonist (Correct Answer)
- D. NK1 receptor antagonist
Pharmacological Management of Obesity Explanation: ***5HT4 receptor agonist***
- Tegaserod is a **selective serotonin 5-HT4 receptor partial agonist** that facilitates the release of neurotransmitters.
- This action **stimulates the peristaltic reflex** and intestinal secretion, thereby accelerating intestinal transit and alleviating symptoms of **irritable bowel syndrome with constipation (IBS-C)**.
*5HT3 receptor antagonist*
- **5-HT3 receptor antagonists** (e.g., ondansetron) are primarily used as **antiemetics** to prevent nausea and vomiting.
- They work by blocking serotonin's action at 5-HT3 receptors in the gastrointestinal tract and the **chemoreceptor trigger zone** in the brain.
*Dopamine D2 receptor antagonist*
- **Dopamine D2 receptor antagonists** (e.g., metoclopramide) are used as **prokinetics** and antiemetics due to their ability to block dopamine's inhibitory effect on gastrointestinal motility.
- They increase **gastric emptying** and intestinal transit, but this is not the primary mechanism of tegaserod.
*NK1 receptor antagonist*
- **Neurokinin-1 (NK1) receptor antagonists** (e.g., aprepitant) are primarily used for their **antiemetic properties**, particularly in chemotherapy-induced nausea and vomiting.
- They block the action of **substance P** at the NK1 receptor, which is involved in the emetic reflex.
Pharmacological Management of Obesity Indian Medical PG Question 4: According to standard clinical practice guidelines, significant weight loss requiring medical evaluation is defined as:
- A. 5% weight loss in 1-2 months
- B. 10% weight loss in 2-3 months (Correct Answer)
- C. 5% weight loss in 2-3 months
- D. 10% weight loss in 1-2 months
Pharmacological Management of Obesity Explanation: ***10% weight loss in 2-3 months***
- **Unexplained weight loss** of **10%** or more of usual body weight over a period of **2-3 months** is generally considered a significant amount requiring medical evaluation.
- This degree of weight loss can be indicative of underlying serious medical conditions like cancer, gastrointestinal disorders, endocrine disorders, or chronic infections [1].
*5% weight loss in 1-2 months*
- While any unexplained weight loss should be noted, a **5% loss** in this timeframe is usually not considered immediately "significant" enough to warrant an aggressive workup unless other concerning symptoms are present.
- It might be due to minor lifestyle changes, temporary illness, or benign factors.
*5% weight loss in 2-3 months*
- A **5% weight loss** over **2-3 months** is a less critical threshold than 10% for initiating an extensive medical evaluation for serious underlying disease.
- This level of weight change could be due to a variety of less severe causes or even normal fluctuations.
*10% weight loss in 1-2 months*
- While a **10% weight loss** is significant, the **1-2 month** timeframe is generally considered slightly too short to immediately classify it as "requiring medical evaluation" in the strictest sense compared to the 2-3 month period which allows for better observation.
- Rapid weight loss over a very short period might sometimes be related to acute illness or dehydration rather than chronic underlying conditions, though still warrants attention.
Pharmacological Management of Obesity Indian Medical PG Question 5: A 50-year-old woman, who is 5 feet 7 inches tall and weighs 185 pounds, has a family history of diabetes mellitus. Her fasting blood glucose levels are 160 mg/dL and 155 mg/dL on two occasions, and her HbA1c level is 7.9%. After being educated on medical nutrition therapy, she returns for reevaluation in 8 weeks, reporting that she has followed diet and exercise recommendations, but her fasting blood glucose levels remain between 140 and 150 mg/dL, and her HbA1c level is 7.7%. She is asymptomatic, and physical examination reveals no abnormalities. Which of the following treatments is the most appropriate for her condition?
- A. Metformin (Correct Answer)
- B. A thiazolidinedione
- C. A dipeptidyl peptidase-4 (DPP-4) inhibitor
- D. Insulin therapy
Pharmacological Management of Obesity Explanation: ***Metformin***
- **Metformin** is the **first-line pharmacological treatment** for type 2 diabetes mellitus when lifestyle modifications are insufficient, as seen in this patient whose blood glucose and HbA1c remain elevated after 8 weeks of diet and exercise [1].
- It works by **decreasing hepatic glucose production** and **improving insulin sensitivity**, and it has a favorable safety profile, including no risk of hypoglycemia and potential for weight neutrality or modest weight loss [1].
*A thiazolidinedione*
- **Thiazolidinediones** (e.g., pioglitazone) are effective in improving insulin sensitivity but are typically considered **second-line agents** or used in patients who cannot tolerate metformin.
- They are associated with side effects such as **weight gain**, **fluid retention**, and an increased risk of heart failure, which might not be ideal for initial therapy.
*A dipeptidyl ppetidase-4 (DPP-4) inhibitor*
- **DPP-4 inhibitors** (e.g., sitagliptin) enhance insulin secretion and suppress glucagon secretion in a glucose-dependent manner, offering good glycemic control with a low risk of hypoglycemia.
- However, they are **less potent** than metformin in lowering HbA1c and are generally used as **second-line therapy** or in combination with metformin.
*Insulin therapy*
- **Insulin therapy** is indicated for patients with **markedly elevated glucose levels** (e.g., HbA1c > 10% or fasting plasma glucose > 250 mg/dL), significant symptoms of hyperglycemia, or when other oral agents have failed.
- This patient's HbA1c of 7.7% and asymptomatic status suggest that oral agents should be attempted first before resorting to insulin.
Pharmacological Management of Obesity Indian Medical PG Question 6: At which positions does pancreatic lipase hydrolyze the ester linkages of triacylglycerides?
- A. 1 and 2
- B. 2 and 3
- C. Only 3
- D. 1 and 3 (Correct Answer)
Pharmacological Management of Obesity Explanation: **Correct: 1 and 3**
- Pancreatic lipase specifically targets the **ester bonds at the sn-1 and sn-3 positions** (primary alcohol positions) on the glycerol backbone of triacylglycerides.
- This positional specificity results in the formation of **2-monoacylglycerol (2-MAG)** and **two free fatty acids**.
- This is the characteristic action of pancreatic triacylglycerol lipase during fat digestion in the intestinal lumen.
*Incorrect: 1 and 2*
- Hydrolysis at positions 1 and 2 would produce a 3-monoacylglycerol and free fatty acids, which is not the physiological product of pancreatic lipase.
- The enzyme's positional specificity favors the outer sn-1 and sn-3 positions, not the middle sn-2 position.
*Incorrect: 2 and 3*
- Hydrolysis at positions 2 and 3 would yield a 1-monoacylglycerol and free fatty acids, which does not reflect pancreatic lipase activity.
- The enzyme specifically spares the sn-2 position due to its structural specificity.
*Incorrect: Only 3*
- If only position 3 were hydrolyzed, the product would be a 1,2-diacylglycerol and one free fatty acid.
- This represents incomplete hydrolysis; pancreatic lipase typically hydrolyzes **both outer positions (sn-1 and sn-3)** due to its regiospecificity.
Pharmacological Management of Obesity Indian Medical PG Question 7: Which of the following inhibits appetite by counteracting the effects of neuropeptide Y?
- A. Orexins
- B. Leptin (Correct Answer)
- C. Neuropeptide Y
- D. Ghrelin
Pharmacological Management of Obesity Explanation: ***Leptin***
- **Leptin** is a hormone primarily produced by **adipose tissue** that signals satiety to the brain, effectively counteracting the appetite-stimulating effects of neuropeptide Y.
- It acts on receptors in the **hypothalamus** to reduce food intake and increase energy expenditure, thereby inhibiting appetite.
*Orexins*
- **Orexins** (also known as hypocretins) are **neurotransmitters** involved in regulating **wakefulness** and appetite.
- Their primary role related to appetite is typically to **stimulate hunger** and food seeking behavior, rather than inhibiting it.
*Neuropeptide Y*
- **Neuropeptide Y (NPY)** is a potent **orexigenic peptide**, meaning it **stimulates appetite** and food intake.
- It promotes the consumption of carbohydrates and is a key mediator of hunger signals in the brain through its action on the **hypothalamus**.
*Ghrelin*
- **Ghrelin** is a hormone produced mainly in the **stomach** that acts as a strong **appetite stimulant**.
- It is often referred to as the "**hunger hormone**" and its levels rise before meals, signaling the brain to initiate food seeking.
Pharmacological Management of Obesity Indian Medical PG Question 8: Match the following drugs in Column A with their contraindications in Column B.
| Column A | Column B |
| :-- | :-- |
| 1. Morphine | 1. QT prolongation |
| 2. Amiodarone | 2. Thromboembolism |
| 3. Vigabatrin | 3. Pregnancy |
| 4. Estrogen preparations | 4. Head injury |
- A. A-1, B-3, C-2, D-4
- B. A-4, B-1, C-3, D-2 (Correct Answer)
- C. A-3, B-2, C-4, D-1
- D. A-2, B-4, C-1, D-3
Pharmacological Management of Obesity Explanation: ***A-4, B-1, C-3, D-2***
- **Morphine** is contraindicated in **head injury** as it can increase intracranial pressure and mask neurological symptoms.
- **Amiodarone** is contraindicated in patients with **QT prolongation** due to its risk of inducing more severe arrhythmias like Torsades de Pointes.
- **Vigabatrin** is contraindicated during **pregnancy** due to its potential for teratogenicity and adverse effects on fetal development.
- **Estrogen preparations** are contraindicated in patients with a history of **thromboembolism** due to their increased risk of blood clot formation.
*A-1, B-3, C-2, D-4*
- This option incorrectly matches **Morphine** with QT prolongation and **Estrogen preparations** with head injury, which are not their primary contraindications.
- It also incorrectly links **Vigabatrin** with thromboembolism and **Amiodarone** with pregnancy.
*A-3, B-2, C-4, D-1*
- This choice incorrectly associates **Morphine** with pregnancy and **Vigabatrin** with head injury, which are not the most critical or direct contraindications.
- It also misaligns **Amiodarone** with thromboembolism and **Estrogen preparations** with QT prolongation.
*A-2, B-4, C-1, D-3*
- This option incorrectly matches **Morphine** with thromboembolism and **Amiodarone** with head injury, which are not their most significant contraindications.
- It also incorrectly links **Vigabatrin** with QT prolongation and **Estrogen preparations** with pregnancy.
Pharmacological Management of Obesity Indian Medical PG Question 9: Appetite is stimulated by all except
- A. Neuropeptide Y
- B. Agouti related peptide
- C. Melanocyte concentrating hormone
- D. Melanocyte stimulating hormone (Correct Answer)
Pharmacological Management of Obesity Explanation: ***Melanocyte stimulating hormone***
- **Alpha-melanocyte stimulating hormone (α-MSH)** is a catabolic hormone that acts to reduce appetite and increase energy expenditure.
- It is an **anorexigenic peptide** that suppresses feeding by binding to central melanocortin receptors, primarily MC4R.
*Neuropeptide Y*
- **Neuropeptide Y (NPY)** is a potent **orexigenic peptide** that stimulates appetite and food intake.
- It plays a crucial role in regulating energy balance and is increased during fasting states.
*Agouti related peptide*
- **Agouti-related peptide (AgRP)** is a strong **orexigenic peptide** that increases food intake.
- It acts as an **antagonist** at the MC3R and MC4R melanocortin receptors, counteracting the appetite-suppressing effects of α-MSH.
*Melanocyte concentrating hormone*
- **Melanin-concentrating hormone (MCH)** is an **orexigenic neuropeptide** that stimulates feeding behavior.
- It is primarily expressed in the lateral hypothalamus and plays a significant role in promoting appetite and weight gain.
Pharmacological Management of Obesity Indian Medical PG Question 10: Which of the following is true regarding the treatment of cocaine withdrawal symptoms?
- A. Fluoxetine
- B. Antidepressants
- C. No specific drug (Correct Answer)
- D. Benzodiazepines
Pharmacological Management of Obesity Explanation: ***No specific drug***
- Currently, there is **no FDA-approved pharmacotherapy** for the treatment of cocaine withdrawal symptoms or for preventing relapse in cocaine dependence.
- Management primarily focuses on **supportive care**, **psychotherapy** (cognitive behavioral therapy, contingency management), and addressing **co-occurring mental health disorders**.
- Unlike alcohol or opioid withdrawal, cocaine withdrawal is not life-threatening and does not require specific medication.
*Fluoxetine*
- Fluoxetine is a **selective serotonin reuptake inhibitor (SSRI)** primarily used to treat depression and anxiety disorders.
- While depression can be a symptom of cocaine withdrawal, fluoxetine has **not been shown to be effective** for reducing cocaine use or treating cocaine withdrawal specifically.
- Multiple clinical trials have failed to demonstrate benefit for cocaine dependence treatment.
*Antidepressants*
- While various antidepressants (including desipramine, bupropion) have been investigated, there is **no strong evidence** to support their routine use as primary treatment for cocaine withdrawal or dependence.
- Their effectiveness in this context is **limited and inconsistent** across studies.
- They may be used to treat **co-occurring depressive disorders** but not as primary cocaine withdrawal treatment.
*Benzodiazepines*
- Benzodiazepines are primarily used to manage **acute anxiety and seizures** during withdrawal from GABAergic substances like **alcohol and sedatives**.
- They are generally **not recommended** for cocaine withdrawal as cocaine withdrawal does not cause seizures or dangerous autonomic instability.
- May be used only for **severe agitation** or **co-occurring alcohol withdrawal**, but carry their own dependence potential and do not address cocaine withdrawal itself.
More Pharmacological Management of Obesity Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
